Pelthos Therapeutics (PTHS) stock: insider trades, news & valuation
Net buyingShare price and insider trades
Pelthos Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $1000K and 5 sold $486K of PTHS stock on the open market.
Get emailed when insiders cluster-buy stocks like PTHS
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
PTHS insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $45K | 3 |
| Q3 2026 | — | 0 | $56K | 6 |
| Q2 2026 | $1000K | 2 | $105K | 11 |
| Q1 2026 | — | 0 | — | 0 |
| Q4 2025 | — | 0 | $280K | 4 |
Valuation, profit and volume
Summary
Over the past 12 months, 1 Pelthos Therapeutics Inc. insider reported open-market purchases totaling $1000K, while 5 insiders reported sales totaling $486K. 19 of 24 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 6SEC | Peter GreenleafDirector | Sell Plan | 79723,087 held (−3%) | $21.17 | $17K | -3.2% | — |
| Oct 6SEC | Matthew PaulsDirector | Sell Plan | 78613,578 held (−5%) | $21.00 | $17K | -2.4% | — |
| Oct 6SEC | Ezra M FriedbergDirector | Sell Plan | 55880,484 held (−1%) | $20.72 | $12K | -1.0% | — |
| Jul 7SEC | Peter GreenleafDirector | Sell Plan | 71223,969 held (−3%) | $26.00 | $19K | -21.2% | — |
| Jul 7SEC | Matthew PaulsDirector | Sell Plan | 69214,458 held (−5%) | $26.00 | $18K | -21.2% | — |
| Jul 7SEC | Ezra M FriedbergDirector | Sell Plan | 53481,066 held (−1%) | $26.03 | $14K | -21.2% | — |
| Jul 7SEC | Matthew PaulsDirector | Sell Plan | 9414,364 held (−1%) | $27.36 | $3K | -25.1% | — |
| Jul 7SEC | Peter GreenleafDirector | Sell Plan | 8523,884 held (−0%) | $27.27 | $2K | -24.8% | — |
| Jul 7SEC | Ezra M FriedbergDirector | Sell Plan | 2481,042 held (−0%) | $27.33 | $656 | -25.0% | — |
| Jun 17SEC | Ezra M FriedbergDirector | Sell Plan | 22481,659 held (−0%) | $27.12 | $6K | -24.4% | — |
| Jun 17SEC | Ezra M FriedbergDirector | Sell Plan | 5981,600 held (−0%) | $27.94 | $2K | -26.6% | — |
| Jun 15SEC | Todd C DavisDirector | Buy | 35,44575,331 held (+89%) | $27.80 | $985K | -26.3% | — |
| Jun 15SEC | Todd C DavisDirector | Buy | 50375,834 held (+1%) | $28.73 | $14K | -28.6% | — |
| May 26SEC | Knuettel Francis IICFO | Sell | 1,50011,316 held (−12%) | $26.84 | $40K | -23.6% | — |
| Apr 6SEC | Peter GreenleafDirector | Sell Plan | 42025,058 held (−2%) | $20.52 | $9K | -0.1% | — |
| Apr 6SEC | Matthew PaulsDirector | Sell Plan | 41515,521 held (−3%) | $20.52 | $9K | -0.1% | — |
| Apr 6SEC | Peter GreenleafDirector | Sell Plan | 37724,681 held (−2%) | $21.36 | $8K | -4.0% | — |
| Apr 6SEC | Matthew PaulsDirector | Sell Plan | 37115,150 held (−2%) | $21.36 | $8K | -4.0% | — |
| Apr 6SEC | Richard MalamutDirector | Sell Plan | 31027,702 held (−1%) | $20.51 | $6K | -0.0% | — |
| Apr 6SEC | Ezra M FriedbergDirector | Sell Plan | 29382,292 held (−0%) | $20.51 | $6K | -0.0% | — |
| Apr 6SEC | Richard MalamutDirector | Sell Plan | 28027,422 held (−1%) | $21.36 | $6K | -4.0% | — |
| Apr 6SEC | Ezra M FriedbergDirector | Sell Plan | 26582,027 held (−0%) | $21.36 | $6K | -4.0% | — |
| Nov 26SEC | Ezra M FriedbergDirector | Sell | 5,99934,001 held (−15%) | $28.00 | $168K | -26.8% | — |
| Nov 26SEC | Ezra M FriedbergDirector | Sell | 2,00032,001 held (−6%) | $28.14 | $56K | -27.1% | — |
| Nov 26SEC | Ezra M FriedbergDirector | Sell | 2,00030,000 held (−6%) | $28.01 | $56K | -26.8% | — |
| Nov 26SEC | Ezra M FriedbergDirector | Sell | 132,000 held (−0%) | $28.50 | $28 | -28.1% | — |
Insiders at Pelthos Therapeutics Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Todd C DavisDirector | $1000K | — | Jun 15, 2026 | — |
| Ezra M FriedbergDirector | — | $326K | Oct 6, 2026 | — |
| Peter GreenleafDirector | — | $54K | Oct 6, 2026 | — |
| Matthew PaulsDirector | — | $54K | Oct 6, 2026 | — |
| Knuettel Francis IICFO | — | $40K | May 26, 2026 | — |
| Richard MalamutDirector | — | $12K | Apr 6, 2026 | — |
PTHS stock: common questions
Are Pelthos Therapeutics Inc. insiders buying PTHS stock?
In the past 12 months, 1 insiders reported open-market purchases of PTHS worth $1000K. The latest was Director Todd C Davis bought $985K of PTHS at $27.80 — first open-market purchase in our records; raises the stake by 89%.
Are Pelthos Therapeutics Inc. insiders selling PTHS stock?
5 insiders reported sales worth $486K over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is PTHS's 52-week range?
Over the past year PTHS has traded between $18.19 and $37.42. It last closed at $20.50 on Oct 9, 2026.